This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Walgreens Tumbles on Costly Global Deal (Update 1)

The deal has benefits, such as creating new growth opportunities for Walgreens and its shareholders. "We applaud Walgreen management for no longer sitting on its hands from a strategic perspective given the ongoing Express Scripts impasse," wrote UBS analyst Jason DeRise in a Tuesday note to clients.

"Our sense is that investors will now begin to refocus on Walgreen as more of a growth investment opportunity as opposed to trading opportunity around a potential resolution (or lack thereof) to the ESRX dispute."

Separately, Walgreens reported fiscal third quarter earnings per share of 62 cents, meeting street estimates; however, a sales fell 3.4% year-over-year to $17.8 billion, slightly missing estimates. Last month, Nottingham, England -based Alliance Boots reported a 12% increase in annual profit, on growth at its wholesale pharmaceuticals business

In a sense, the deal marks a second attempt to buy Alliance Boots and turn a profit. In 2007, KKR and Alliance Boots Chairman Stefano Pessina took the company private in $12 billion pound buyout that was the largest private equity deal at the time. Since then, KKR says that Alliance Boots profits have surged 88%.

As part of 45% stake acquisition by Walgreen, KKR will receive $2 billion in cash and stock for roughly half of its Alliance Boots stake after it made a $2.45 billion investment in 2007. The private equity giant will also gain a seat on Walgreen's board.

"We are looking forward to working with Alliance Boots to leverage our combined strengths and provide an even broader range of innovative, cost-effective products and services to patients and customers across the healthcare landscape," said Walgreens chief executive Gregory Wasson, of Tuesday's stake acquisition.

"Together we will be ideally positioned to expand our customer offerings in our existing markets and become the health and wellbeing partner of choice in emerging markets."

That strategy counters other long-speculated options for Walgreens, including a takeover of debt-laden pharmacy and drug store giant Rite Aid (RAD).

In November, Susquehanna Financial Group analyst Joseph Stauff wrote in a note to clients that Rite Aid could be a target of Walgreen, the largest U.S. drugstore chain. With Rite Aid, Walgreen would further bolster its near 30% market share, distancing it from CVS Caremark (CVS), the industry second, noted Stauff.

In March, Credit Suisse analyst Edward Kelly said that a Rite Aid acquisition would help Walgreen push against drugstore competition by pharmacy benefits managers like CVS Caremark and Express Scripts, which completed a $29 billion 2011 acquisition of Medco Health Solutions (MHS).

Tuesday's deal counters those expectations and Walgreens previous M&A history, as it shifts its strategy internationally. In 2010, Walgreen spent $1.1 billion to buy New York-based drug-store chain Duane Reade from private equity firm Oak Hill Capital and was a bidder for Longs Drug Stores, another U.S. chain that was eventually bought by CVS Caremark.

For more on investing in drug stores and pharmacy giants see why Rite Aid's earnings overtake deal hopes and why Express Scripts could be sandbagging synergies.

-- Written by Antoine Gara in New York

Stock quotes in this article: WAG, ESRX, CVS, RAD, KKR 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs